These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 18222355)
1. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Iakoubova OA; Sabatine MS; Rowland CM; Tong CH; Catanese JJ; Ranade K; Simonsen KL; Kirchgessner TG; Cannon CP; Devlin JJ; Braunwald E J Am Coll Cardiol; 2008 Jan; 51(4):449-55. PubMed ID: 18222355 [TBL] [Abstract][Full Text] [Related]
2. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJ; Circ Cardiovasc Genet; 2012 Feb; 5(1):51-7. PubMed ID: 22135385 [TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Shiffman D; Sabatine MS; Louie JZ; Kirchgessner TG; Iakoubova OA; Campos H; Devlin JJ; Sacks FM Am J Cardiol; 2010 May; 105(9):1300-5. PubMed ID: 20403483 [TBL] [Abstract][Full Text] [Related]
4. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Iakoubova OA; Robertson M; Tong CH; Rowland CM; Catanese JJ; Blauw GJ; Jukema JW; Murphy MB; Devlin JJ; Ford I; Shepherd J Eur J Cardiovasc Prev Rehabil; 2010 Aug; 17(4):455-61. PubMed ID: 20215968 [TBL] [Abstract][Full Text] [Related]
5. KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. Li Y; Iakoubova OA; Shiffman D; Devlin JJ; Forrester JS; Superko HR Am J Cardiol; 2010 Oct; 106(7):994-8. PubMed ID: 20854963 [TBL] [Abstract][Full Text] [Related]
6. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575 [TBL] [Abstract][Full Text] [Related]
8. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. Iakoubova OA; Tong CH; Rowland CM; Kirchgessner TG; Young BA; Arellano AR; Shiffman D; Sabatine MS; Campos H; Packard CJ; Pfeffer MA; White TJ; Braunwald E; Shepherd J; Devlin JJ; Sacks FM J Am Coll Cardiol; 2008 Jan; 51(4):435-43. PubMed ID: 18222353 [TBL] [Abstract][Full Text] [Related]
9. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061 [TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome. Parthan A; Leahy KJ; O'Sullivan AK; Iakoubova OA; Bare LA; Devlin JJ; Weinstein MC Pharmacoeconomics; 2013 Jun; 31(6):519-31. PubMed ID: 23585310 [TBL] [Abstract][Full Text] [Related]
11. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. Hopewell JC; Parish S; Clarke R; Armitage J; Bowman L; Hager J; Lathrop M; Collins R; J Am Coll Cardiol; 2011 May; 57(20):2000-7. PubMed ID: 21458191 [TBL] [Abstract][Full Text] [Related]
12. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923 [TBL] [Abstract][Full Text] [Related]
13. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Rouleau J Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805 [TBL] [Abstract][Full Text] [Related]
14. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP; J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964 [TBL] [Abstract][Full Text] [Related]
15. Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease. Williams P; Pendyala L; Superko R BMC Med Genet; 2011 Mar; 12():42. PubMed ID: 21435211 [TBL] [Abstract][Full Text] [Related]
16. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Wiviott SD; de Lemos JA; Cannon CP; Blazing M; Murphy SA; McCabe CH; Califf R; Braunwald E Circulation; 2006 Mar; 113(11):1406-14. PubMed ID: 16534008 [TBL] [Abstract][Full Text] [Related]
17. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Ray KK; Cannon CP Curr Opin Lipidol; 2004 Dec; 15(6):637-43. PubMed ID: 15529022 [TBL] [Abstract][Full Text] [Related]
18. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E; J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164 [TBL] [Abstract][Full Text] [Related]
19. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260 [TBL] [Abstract][Full Text] [Related]
20. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]